Respiratory Pathogen Detection
The rapid and accurate detection of respiratory pathogens is important. Potential advantages of specific pathogen detection include obtaining prognostic information, limiting additional testing, instituting appropriate infection control precautions and limiting unnecessary antibiotic usage1.
Molecular methods offer the advantages of rapidity and the ability to detect pathogens regardless of growth requirements or the availability of reagents for rapid diagnostic testing1.
The EasyScreen™ Respiratory Kits are based on real-time PCR and is a qualitative in vitro diagnostic test for the detection of selected target nucleic acids, in respiratory specimens treated using an EasyScreen™ Sample Processing Kit. The device specifically detects nucleic acid sequences from viral and bacterial pathogens of the respiratory system. Compatible specimens include swabs (dry, or in UTM), sputum, bronchial washings, and Nasopharyngeal Aspirates.
The EasyScreen™ Respiratory Pathogen Detection Kit (RP007/RP007-HT) is a rapid in vitro nucleic acid amplification assay for the qualitative detection of respiratory pathogen nucleic acid from respiratory specimens.
Molecular methods offer the advantages of rapidity and the ability to detect pathogens regardless of growth requirements or the availability of reagents for rapid diagnostic testing. The kit uses multiplexed real-time PCR assays and is compatible with nucleic acids isolated using an appropriate EasyScreen™ Sample Processing Kit.
EasyScreen™ Respiratory Pathogen targets (RP007/RP007-HT)
|Rhinovirus||Parainfluenza 1/3||Mycoplasma pneumoniae|
|Respiratory syncytial virus- A/B||Parainfluenza 2|
The kit also includes an Extraction Process Control (LEPC) in order to determine the reliability of the extracted nucleic acids, validate the reverse transcription process and indicate the presence of any inhibitors after extraction from primary samples.
- The EasyScreen™ Respiratory Pathogen Detection Kit (RP007/RP007-HT) is for In vitro Diagnostic Use Only
The Genetic Signatures’ EasyScreenTM Atypical Respiratory Pathogen Detection Kit (RP009/RP009-HT) has been designed to provide rapid and accurate detection of multiple atypical respiratory pathogens. The kit uses multiplexed real-time PCR and is compatible with nucleic acid isolated using the EasyScreenTM Sample Processing Kit.
EasyScreen™ Atypical Respiratory targets (RP009/RP009-HT)
|Legionella longbeachae||Mycoplasma pneumonia||Legionella pneumophila|
|Chlamydophila pneumoniae||Pneumocystis jirovecii||Chlamydophila psittaci|
The kit also includes an extraction controls to ensure the quality of extracted nucleic acids and detect the presence of any inhibitors.
- The EasyScreen™ Atypical Respiratory Pathogen Detection Kit (RP009/RP009-HT) is for research use only
Coronaviruses (CoV) are a family of viruses, transmitted between animals and people, known to cause illnesses ranging in severity from the common cold to more severe diseases such as the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS)1. The novel coronavirus SARS-CoV-2 is the seventh known coronavirus to infect humans (others are 229E, NL63, OC43, HKU1, MERS-CoV and SARS-CoV), with the first reported case of the current SAR-CoV-2 (formally known as 2019-nCoV) outbreak originating from Wuhan, China on the 31st December 20192.
The Genetic Signatures’ EasyScreen™ SARS-CoV-2 Detection Kit (RP011/RP011-HT) has been designed to provide rapid and accurate detection of SARS-CoV-2.
EasyScreen™ SARS-CoV-2 Detection Targets (RP011/RP011-HT)
The test, based on real-time PCR, enables detection of SARS-CoV-2 via 2 gene targets. The Nucleocapsid (N-gene) in both the SARS and SARS- CoV-2 genome and the E-gene of SARS-CoV-2.
The kit also includes a control to ensure the quality of extracted nucleic acids, the integrity of PCR reagents and detect the presence of any inhibitors.
- The EasyScreenTM SARS-CoV-2 Detection Kit (RP011/RP011-HT) is for in vitro diagnostic use
1Zhu, Na; Zhang, Dingyu; Wang, Wenling; Li, Xinwang; Yang, Bo; Song, Jingdong; Zhao, Xiang; Huang, Baoying; Shi, Weifeng; Lu, Roujian; Niu, Peihua; Zhan, Faxian; Ma, Xuejun; Wang, Dayan; Xu, Wenbo; Wu, Guizhen; Gao, George F.; Tan, Wenjie (24 January 2020). “A Novel Coronavirus from Patients with Pneumonia in China, 2019”. New England Journal of Medicine. United States. doi:10.1056/ NEJMoa2001017. ISSN 0028-4793. PMID 31978945.
2Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. World Health Organization, 17 January 2020. https://www.who.int/publications-detail/laboratory-testing-for- 2019-novel-coronavirus-in-suspected-human-cases-20200117